PriceTargets.com logo

Anavex Life Sciences - AVXL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $44.00
  • Forecasted Upside: 356.91%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$9.63 As of 04/29/2025 05:00 PM ET
▲ +0.05 (0.52%)

This chart shows the closing price for AVXL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Anavex Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVXL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVXL

Analyst Price Target is $44.00
▲ +356.91% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Anavex Life Sciences in the last 3 months. The average price target is $44.00, with a high forecast of $46.00 and a low forecast of $42.00. The average price target represents a 356.91% upside from the last price of $9.63.

This chart shows the closing price for AVXL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Anavex Life Sciences. This rating has held steady since October 2024, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/6/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/4/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2025

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
4/7/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
3/31/2025HC WainwrightReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
2/18/2025HC WainwrightReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
2/12/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
1/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
1/28/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
1/21/2025HC WainwrightReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
1/13/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
12/26/2024HC WainwrightBoost TargetBuy ➝ Buy$40.00 ➝ $42.00
12/23/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
11/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
11/25/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
11/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
10/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
7/22/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
6/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00
1/3/2024HC WainwrightLower TargetBuy ➝ Buy$54.00 ➝ $40.00
11/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$54.00
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$54.00
3/31/2023HC WainwrightBoost TargetBuy$50.00 ➝ $54.00
2/9/2023BTIG ResearchLower TargetBuy$35.00 ➝ $28.00
2/6/2023HC WainwrightReiterated RatingBuy$50.00
1/3/2023HC WainwrightBoost TargetBuy$42.00 ➝ $50.00
12/6/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral$16.00 ➝ $11.00
12/2/2022JonestradingBoost Target$40.00 ➝ $80.00
6/23/2022Berenberg BankInitiated CoverageBuy$40.00
3/16/2022HC WainwrightReiterated RatingBuy$42.00
2/2/2022HC WainwrightBoost TargetBuy$39.00 ➝ $42.00
11/25/2021BTIG ResearchReiterated RatingBuy$34.00
11/19/2021BTIG ResearchReiterated RatingBuy$35.00
10/14/2021HC WainwrightReiterated RatingBuy$39.00
9/23/2021BTIG ResearchInitiated CoverageBuy$35.00
6/28/2021Cantor FitzgeraldBoost TargetOverweight$31.00 ➝ $40.00
6/28/2021HC WainwrightReiterated RatingBuy$25.00 ➝ $39.00
6/21/2021Dawson JamesBoost TargetBuy$19.00 ➝ $35.00
6/15/2021HC WainwrightBoost TargetBuy$17.00 ➝ $25.00
6/14/2021JonestradingReiterated RatingBuy$35.00
3/1/2021Cantor FitzgeraldReiterated RatingOverweight$10.00 ➝ $25.00
2/23/2021Cantor FitzgeraldBoost TargetOverweight$10.00 ➝ $25.00
2/17/2021LADENBURG THALM/SH SHReiterated RatingBuy$20.00
12/16/2020HC WainwrightBoost TargetPositive ➝ Buy$14.00 ➝ $17.00
10/21/2020HC WainwrightBoost TargetBuy$12.00 ➝ $14.00
9/28/2020LADENBURG THALM/SH SHInitiated CoverageBuy$12.00
8/11/2020HC WainwrightReiterated RatingBuy
6/16/2020HC WainwrightReiterated RatingBuy$12.00
6/8/2020Dawson JamesReiterated RatingBuy$16.00
6/8/2020Janney Montgomery ScottReiterated RatingBuy$10.00
6/8/2020Cantor FitzgeraldReiterated RatingBuy$8.00
6/5/2020HC WainwrightReiterated RatingBuy$12.00
5/22/2020HC WainwrightReiterated RatingBuy$12.00
5/8/2020HC WainwrightReiterated RatingBuy$12.00
(Data available from 4/30/2020 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/2/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/1/2024
  • 4 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/1/2024
  • 8 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/31/2024
  • 8 very positive mentions
  • 23 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/30/2025
  • 3 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2025
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2025
  • 7 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2025

Current Sentiment

  • 7 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Anavex Life Sciences logo
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Read More

Today's Range

Now: $9.63
Low: $9.42
High: $9.67

50 Day Range

MA: $8.83
Low: $7.60
High: $9.93

52 Week Range

Now: $9.63
Low: $3.51
High: $14.44

Volume

440,755 shs

Average Volume

1,222,700 shs

Market Capitalization

$819.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Anavex Life Sciences?

The following Wall Street research analysts have issued research reports on Anavex Life Sciences in the last twelve months: D. Boral Capital, EF Hutton Acquisition Co. I, and HC Wainwright.
View the latest analyst ratings for AVXL.

What is the current price target for Anavex Life Sciences?

0 Wall Street analysts have set twelve-month price targets for Anavex Life Sciences in the last year. Their average twelve-month price target is $44.00, suggesting a possible upside of 356.9%. D. Boral Capital has the highest price target set, predicting AVXL will reach $46.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $42.00 for Anavex Life Sciences in the next year.
View the latest price targets for AVXL.

What is the current consensus analyst rating for Anavex Life Sciences?

Anavex Life Sciences currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AVXL will outperform the market and that investors should add to their positions of Anavex Life Sciences.
View the latest ratings for AVXL.

What other companies compete with Anavex Life Sciences?

Other companies that are similar to Anavex Life Sciences include Merus, Crinetics Pharmaceuticals, Scholar Rock, Viking Therapeutics and Xenon Pharmaceuticals. Learn More about companies similar to Anavex Life Sciences.

How do I contact Anavex Life Sciences' investor relations team?

Anavex Life Sciences' physical mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company's listed phone number is (844) 689-3939 and its investor relations email address is [email protected]. The official website for Anavex Life Sciences is www.anavex.com. Learn More about contacing Anavex Life Sciences investor relations.